Exclusive: EMA looks into clinical trial issues in India in wake of US trial cancellations
This article was originally published in SRA
Following recent reports that the US government had stopped clinical trials it was sponsoring in India due to concerns over new regulations in the country, the European Medicines Agency has confirmed that it has "approached the Indian drug controller to learn more about these issues and any possible implication on trials to be included in European applications"1,2.
You may also be interested in...
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.